Ariad suspends Iclusig sales 'temporarily' on FDA concerns; shares plummet
This article was originally published in Scrip
Shares of Ariad Pharmaceuticals took another beating on 31 October, spiraling down as low as 45.7%, after the company, at the FDA's request, temporarily suspended the marketing and commercial distribution of the firm’s oral leukemia drug Iclusig (ponatinib) based on reports of serious and life-threatening blood clots and severe narrowing of blood arteries and veins in patients taking the medicine.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.